ES2090341T3 - 1-alcoholes de prostaglandina (pgf) y sus usos como hipotensivos oculares. - Google Patents

1-alcoholes de prostaglandina (pgf) y sus usos como hipotensivos oculares.

Info

Publication number
ES2090341T3
ES2090341T3 ES91912254T ES91912254T ES2090341T3 ES 2090341 T3 ES2090341 T3 ES 2090341T3 ES 91912254 T ES91912254 T ES 91912254T ES 91912254 T ES91912254 T ES 91912254T ES 2090341 T3 ES2090341 T3 ES 2090341T3
Authority
ES
Spain
Prior art keywords
configuration
alpha
independently
indicate
pgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91912254T
Other languages
English (en)
Inventor
David Frederick Woodward
Ming Fai Chan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2090341T3 publication Critical patent/ES2090341T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE DERIVADOS DE PROSTAGLANDINAS TIPO F DE ALCOHOLES QUE ACTUAN COMO HIPOTENSORES OCULARES. LOS DERIVADOS DE PGF UTILIZADOS SEGUN LA INVENCION QUEDAN REPRESENTADOS POR LA FORMULA ESTRUCTURA (I) EN DONDE LOS ENLACES CON LINEAS ONDULADAS INDICAN BIEN LA CONFIGURACION ALFA (O) O LA BETA ((BETA)); LAS LINEAS RAYADAS INDICAN UNA CONFIGURACION O, LOS TRIANGULOS CON UNA LINEA GRUESA SE UTILIZAN PARA INDICAR UNA CONFIGURACION (BETA), LOS ENLACES CON GUIONES REPRESENTAN UN ENLACE DOBLE, EL ENLACE DOBLE DE LAS POSICIONES 5,6 TIENE UNA CONFIGURACION CIS, O ES UN ENLACE SENCILLO; R ES HIDROGENO O UN GRUPO -(CO)R4; R1, R2 Y R3 SON INDEPENDIENTEMENTE HIDROXILO O GRUPOS -O(CO)R5, EN DONDE R4 Y R5 REPRESENTAN INDEPENDIENTEMENTE UN HIDROCARBURO ACICLICO SATURADO O NO SATURADO QUE TIENE DE 1 A 20 ATOMOS DE CARBONO O -(CH2)NR6 DONDE N ES DE 0 A 10 Y R6 ES UN ANILLO ALIFATICO, AROMATICO O HETEROAROMATICO, R7 Y R8 SON INDEPENDIENTEMENTE HIDROGENO O ALKILO DE UNO A 6 ATOMOS DE CARBONO O LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS.
ES91912254T 1990-06-14 1991-06-11 1-alcoholes de prostaglandina (pgf) y sus usos como hipotensivos oculares. Expired - Lifetime ES2090341T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/538,204 US5238961A (en) 1990-06-14 1990-06-14 Pgf 1-alcohols and their use as ocular hypotensives

Publications (1)

Publication Number Publication Date
ES2090341T3 true ES2090341T3 (es) 1996-10-16

Family

ID=24145936

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91912254T Expired - Lifetime ES2090341T3 (es) 1990-06-14 1991-06-11 1-alcoholes de prostaglandina (pgf) y sus usos como hipotensivos oculares.

Country Status (13)

Country Link
US (1) US5238961A (es)
EP (1) EP0533828B1 (es)
JP (1) JP3139766B2 (es)
KR (1) KR100196769B1 (es)
AT (1) ATE141163T1 (es)
AU (1) AU638587B2 (es)
BR (1) BR9106549A (es)
CA (1) CA2084769A1 (es)
DE (1) DE69121408T2 (es)
ES (1) ES2090341T3 (es)
HU (1) HUT63371A (es)
IE (1) IE912011A1 (es)
WO (1) WO1991019490A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270049A (en) * 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
US5139491A (en) * 1990-12-06 1992-08-18 Allergan, Inc. 2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
US5312832A (en) * 1991-05-17 1994-05-17 Allergan, Inc. Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6124353A (en) * 1992-11-12 2000-09-26 Allergan Sales, Inc. Method of treating ocular hypertension with 8-epi prostaglandins
US5476872A (en) * 1993-10-18 1995-12-19 Allergan, Inc. 1,11-diesters of prostaglandin-F2α having a polar ester group at C-1
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
WO1997045405A1 (en) * 1996-05-28 1997-12-04 Allergan Sales, Inc. Cyclopentan(en)oic acid, 2-alkenyl derivatives as therapeutic agents in the treatment of ocular hypertension
US6770675B2 (en) 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
WO2001055102A1 (fr) * 2000-01-28 2001-08-02 Asahi Glass Company, Limited Nouveau derive difluoroprostaglandine
US6414021B1 (en) * 2000-08-25 2002-07-02 Sucampo Ag Control of intraocular pressure during surgery
US20040216749A1 (en) * 2003-01-23 2004-11-04 Hosheng Tu Vasomodulation during glaucoma surgery
US20040151691A1 (en) 2003-01-30 2004-08-05 Oxman Joel D. Hardenable thermally responsive compositions
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055593A (en) * 1971-02-19 1977-10-25 Alza Corporation Alkyl diethers of prostaglandins
US3940438A (en) * 1971-05-24 1976-02-24 Alza Corporation Crystalline racemic 9α,11α,15(S)-trihydroxy-5-cis,13-trans-prostadienoic acid
US3853854A (en) * 1971-06-24 1974-12-10 Alza Corp Novel 5{40 ,6{40 -dihydro-2h-pyran-4{40 -yl prostaglandin ethers
US4001306A (en) * 1971-12-30 1977-01-04 The Upjohn Company Prostaglandin F.sub.α 15-monoacrylates
US3941886A (en) * 1973-09-21 1976-03-02 Alza Corporation Pharmaceutical compositions containing crystalline racemic 9α, 11α, 15(S)-trihydroxy-5-cis, 13-trans-prostadienoic acid
NL7605381A (nl) * 1975-05-26 1976-11-30 Schering Ag Werkwijze voor het bereiden van prostaanderi- vaten en werkwijze voor het bereiden van een geneesmiddel met prostaglandinewerking.
US4025577A (en) * 1975-06-12 1977-05-24 Exxon Research And Engineering Company Hydroalkylation of paraffins with olefins utilizing hydrogen fluoride and metal pentafluoride catalyst
US4049678A (en) * 1976-03-29 1977-09-20 The Upjohn Company 9-Deoxy-PGD-type, 1,15-lactones
US4016184A (en) * 1975-09-17 1977-04-05 The Upjohn Company 9-Deoxy-9,10-didehydro-PGD1 compounds
US4201873A (en) * 1975-09-17 1980-05-06 The Upjohn Company 9-Deoxy-9,10-didehydro-PGD2 analogs
US4033989A (en) * 1975-09-17 1977-07-05 The Upjohn Company 9-Deoxy-PGF2 Analogs
US4060540A (en) * 1975-09-18 1977-11-29 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenylmethoxy-1-trans-alkenyl-dialkyl alanates
GB2048254B (en) * 1979-04-02 1983-05-25 Upjohn Co 19,20 -didehydro-19-hydroxy and 19-oxo-prostaglandin derivatives
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4883819A (en) * 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4824857A (en) * 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
US4822819A (en) * 1986-11-07 1989-04-18 Alcon Laboratories, Inc. Use of trimoprostil and derivatives in glaucoma therapy
ZA88963B (en) * 1987-02-27 1989-11-29 Allergan Inc Prostaglandins useful for lowering intraocular pressure
DE3871596T3 (de) * 1987-04-03 2000-09-07 Pharmacia & Upjohn Ab, Stockholm Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.
SE8703854D0 (sv) * 1987-10-07 1987-10-07 Pharmacia Ab Prostaglandinderivat for behandling av glaukom eller okuler hypertension
US5139491A (en) * 1990-12-06 1992-08-18 Allergan, Inc. 2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives

Also Published As

Publication number Publication date
WO1991019490A1 (en) 1991-12-26
AU8053991A (en) 1992-01-07
DE69121408T2 (de) 1997-02-20
AU638587B2 (en) 1993-07-01
EP0533828A1 (en) 1993-03-31
JPH05507928A (ja) 1993-11-11
US5238961A (en) 1993-08-24
ATE141163T1 (de) 1996-08-15
JP3139766B2 (ja) 2001-03-05
HUT63371A (en) 1993-08-30
EP0533828A4 (en) 1993-08-11
HU9203920D0 (en) 1993-03-29
CA2084769A1 (en) 1991-12-15
IE912011A1 (en) 1991-12-18
BR9106549A (pt) 1993-06-01
DE69121408D1 (de) 1996-09-19
KR100196769B1 (ko) 1999-06-15
EP0533828B1 (en) 1996-08-14

Similar Documents

Publication Publication Date Title
ES2090341T3 (es) 1-alcoholes de prostaglandina (pgf) y sus usos como hipotensivos oculares.
DK0410785T3 (da) 11-Acylprostaglandiner, som reducerer intraokulartryk
DE60206408D1 (de) Omega-zykloalkyl 17-heteroaryl prostaglandin-e2-analoga als ep2-rezeptoragonisten
ES8500276A1 (es) Procedimiento para preparar n2-acil-9-(1,3-dihidroxi-2-propoximetil)-guaninas y sus sales famaceuticamente aceptables.
ES2130599T3 (es) Pseudoceramidas.
ES513108A0 (es) "procedimiento de preparacion de derivados de 1-fenil-1-hidroxi-etilamina".
ATE127450T1 (de) Prostaglandine.
ES2087477T3 (es) Derivados de pirimidina-4-carboxamida, su preparacion y su aplicacion en terapeutica.
ES2040879T3 (es) Procedimiento de preparacion de derivados pirimidinilaminicos de piperidina.
ES2046500T3 (es) Derivado de la histamina, su preparacion y su aplicacion en terapeutica.
ES2062443T3 (es) Nuevos derivados peptidicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX3847E (es) Procedimiento para la preparacion de delta 15-esteroides
AR247729A1 (es) Procedimiento para preparar nuevos compuestos antiarritmicos
ES496880A0 (es) Un procedimiento para la preparacion de derivados de benzofurano.
ZA816259B (en) 2-(1,4-benzodioxan-2-ylalkyl)imidazoles useful as antidepressants
SE7704616L (sv) Sett att framstella nya 11-desoxi-prostaglandin-fÿ2-derivat
ES520693A0 (es) Un procedimiento para la preparacion de derivados de fenilpiperazina.
SE7701778L (sv) 2,9-dioxatricyklo /4,3,1,0?723?717/ dekaner och forfarande for framstellning derav
ES2059550T3 (es) Derivados de la bencimidazola, su preparacion y su aplicacion en terapeutica.
BR9107155A (pt) 2-decarboxil-2-alcoxialquil prostaglandinas como hipotensivos oculares
ES8600254A1 (es) Un procedimiento para preparar derivados de aminopirimidinona
SE8007569L (sv) Fosningsmedel jemte sett att dermed framstella stabila losningar lempliga for parenteral administration
ES467791A1 (es) Procedimiento para la obtencion de nuevos derivados del 1- fenil-2-amino-1,3-propandiol-n-alcohilo.
MX9201392A (es) Derivados de imidazol y procedimiento para su preparacion.
ES467519A1 (es) Un procedimiento de preparacion de acidos furoil- o tenoil- naftiloxialcohilcarboxilicos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 533828

Country of ref document: ES

FG2A Definitive protection

Ref document number: 533828

Country of ref document: ES